Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Antengene Corporation Limited ( (HK:6996) ) has issued an update.
Antengene Corporation Limited plans to amend its articles of association and adopt a ninth amended and restated memorandum and articles to enable hybrid or fully virtual shareholder meetings, align its governance with the Hong Kong treasury shares regime, and implement various consequential and housekeeping changes. These governance adjustments, which are subject to approval by shareholders at the June 10, 2026 annual general meeting, are intended to modernize Antengene’s corporate infrastructure, enhance flexibility in shareholder engagement, and better align its operations with evolving regulatory and market practices in Hong Kong.
Antengene has secured 32 investigational new drug approvals across the U.S. and Asia and obtained new drug application approvals in 10 Asia-Pacific markets, underlining its growing commercial footprint. Its lead asset XPOVIO (selinexor) is approved in multiple Asia-Pacific jurisdictions and has been included in national insurance schemes in several key markets, which supports revenue visibility and strengthens its competitive position in the regional oncology therapeutics landscape.
The most recent analyst rating on (HK:6996) stock is a Hold with a HK$5.74 price target. To see the full list of analyst forecasts on Antengene Corporation Limited stock, see the HK:6996 Stock Forecast page.
More about Antengene Corporation Limited
Antengene Corporation Limited is a global, R&D-driven, commercial-stage biotech company focused on first-in-class and best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline ranges from preclinical to commercial programs, including in-house assets such as ATG-022, ATG-037, ATG-101 and ATG-125, alongside its proprietary AnTenGager T cell engager platform targeting a spectrum of autoimmune diseases, solid tumors and hematologic malignancies across the U.S. and Asia-Pacific markets.
Average Trading Volume: 3,714,436
Technical Sentiment Signal: Buy
Current Market Cap: HK$3.3B
For detailed information about 6996 stock, go to TipRanks’ Stock Analysis page.